conference

Findings from CALGB/SWOG 80702 and ALTAIR studies were presented during 2025 ASCO GI Cancers Symposium, held January 23-25th.  Click on the trial titles to view full articles. CALGB/SWOG 80702 (NCT01150045) Positive ctDNA status is linked to worse DFS in stage III resected colon cancer, but celecoxib improves outcomes in ctDNA-positive patients. ctDNA status is prognostic for DFS and OS, and predictive of celecoxib benefit in the CALGB/SWOG 80702 trial. Celecoxib did not significantly affect DFS in ctDNA-negative patients, indicating its benefit is specific to ctDNA-positive individuals. Ongoing analyses aim to further elucidate ctDNA's predictive value for adjuvant FOLFOX [...]